CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22,490 enrolled
Drug / intervention
Warfarin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03254134
NCT03254134N/ACompleted
CompareCT.gov

Comparative Effectiveness and Safety Between Warfarin and Dabigatran Using Real World Claims Data of Japanese Non-valvular Atrial Fibrillation Patients

Boehringer Ingelheim·observational·Posted Aug 18, 2017·Updated Jul 9, 2019

In Brief

An observational study evaluating Warfarin and Dabigatran for Atrial Fibrillation. Completed, enrolled 22,490 participants across 1 site.

Detailed Summary

This is a comparative effectiveness and safety study of clinical events among patients taking either dabigatran or warfarin. There is no formal hypothesis to be tested, but rather to provide the estimates on the incidence of stroke and systemic embolism (effectiveness) and bleeding events (safety) using 95% confidence interval for comparison between those non0-valvular atrial fibrillation patients taking dabigatran vs. warfarin using a large, nation-wide claims data in Japan.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 18, 2017
Enrollment StartOct 20, 2017
Primary CompletionOct 30, 2017
Study CompletionNov 3, 2017
TodayJul 2, 2026
Enrollment to primary: 10 daysPosted 8.9 years ago

Interventions

Warfarindrug

patients treated with warfarin

Dabigatrandrug

patients treated with Dabigatran